Home  /  Resource Library  /  Utility of measurable residual disease for predicting treatment outcomes with BCR and BCL2 Targeted therapies in patients with CLL

Utility of measurable residual disease for predicting treatment outcomes with BCR and BCL2 Targeted therapies in patients with CLL

Research article examines minimal residual disease as a prediction of outcome of targeted therapies in chronic lymphocytic leukemia.